Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France

Back

Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)

Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara

Affiliation: Associate Professor,Department of Geriatric Medicine, Graduate School of Medicine, OsakaUniversity, 2-2 Yamada-oka, Suita 565-0871, Japan.

Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction

Abstract:

HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 4
ISSUE: 2
Page: [199 - 206]
Pages: 8
DOI: 10.2174/1566523043346453